News
Why combination LDL-lowering therapy is mandated by guidelines for very high-risk patients: Insights from DA VINCI
News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy According to a simulation study using the DA VINCI data (1), combination LDL-lowering therapy including a PCSK9 inhibitor would result in ~90% of very high-risk patients achieving LDL cholesterol goal, as defined…
read more »
ETESIAN: Phase 2b trial of PCSK9 antisense oligonucleotide
News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy In this study, AZD8233 (ION 449) reduced LDL cholesterol by over 70% on top of statin in patients with dyslipidaemia. The findings follow an initial report at the American College of Cardiology…
read more »
News from ACC.22 – New insights from ORION-10 and ORION-11: inclisiran effective in post-MI patients
Inclisiran was effective in lowering LDL cholesterol and generally well tolerated in patients with a prior myocardial infarction (MI), irrespective of the timing of MI, according to latest data from the ORION-10 and ORION-11 studies. Inclisiran is a small interfering ribonucleic acid (siRNA) therapeutic targeting…
read more »
News from ACC.22 late breaking trials: Results from the APOLLO trial with new RNA therapeutic
Results from the APOLLO trial showed that single doses of SLN360, an investigational short interfering RNA (siRNA), resulted in dose-dependent lowering of plasma lipoprotein(a) [Lp(a)] concentration in adults with high Lp(a) and no pre-existing cardiovascular disease. The trial was simultaneously published in the Journal of…
read more »
News from ACC.22 – Long-term data from HAUSER-OLE in paediatric familial hypercholesterolaemia
Results from the HAUSER Open-Label Extension Study (HAUSER-OLE) (1) show that treatment with evolocumab was well tolerated, safe, and led to substantial reduction in LDL cholesterol in children with heterozygous familial hypercholesterolaemia (FH). As previously reported on PCSK9 Forum, HAUSER-RCT evaluated the efficacy and safety…
read more »
News from ACC.22 late breaking trials: PACMAN-AMI delivers
Results from the PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction) trial using multimodality coronary imaging demonstrate the benefit of starting intensive lipid lowering in the acute setting of acute myocardial infarction (AMI). PCSK9 inhibition on top…
read more »
Consider familial hypercholesterolaemia in young heart attack survivors
Familial hypercholesterolaemia (FH) was more than 30-fold more prevalent among young people surviving an acute coronary syndrome (ACS) compared with the general population, according to this French report. These findings reinforce the need to investigate the possibility of FH in these individuals. Heterozygous FH is…
read more »
Lessons from the HEYMANS registry: do we need to lower LDL thresholds for initiating a PCSK9 inhibitor?
Insights from the HEYMANS registry show that criteria for initiation of the PCSK9 inhibitor in real-world practice are far from optimal. The 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for management of dyslipidaemia underline the need for combination therapy in high-risk individuals to…
read more »
New trials: Inclisiran investigated in adolescents with familial hypercholesterolaemia
Trials of PCSK9-targeted therapies have predominantly focused on adults at increased cardiovascular risk due to elevated LDL cholesterol levels. In the setting of familial hypercholesterolaemia (FH), in which individuals have elevated LDL cholesterol levels from birth, it makes sense to prioritize initiation of treatment in…
read more »
Update from FOURIER: Evolocumab provides benefit in patients with prior PCI
In this latest analysis from FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) (1), evolocumab treatment was associated with significant clinical benefit in patients with prior percutaneous coronary intervention (PCI), who are at high residual risk for multiple types of…
read more »
First data from global homozygous FH registry
News from the Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry, a unique global registry of homozygous familial hypercholesterolaemia (HoFH) patients, highlighted the poor management of this severe condition, especially among less affluent countries (1). FH is an inherited disorder characterised by elevated LDL cholesterol…
read more »
ODYSSEY OUTCOMES analysis targets heart failure
A recent post hoc analysis from ODYSSEY OUTCOMES did not suggest benefit from treatment with alirocumab in heart failure patients (1). The role of statin treatment in patients with heart failure is much debated. Individual randomized controlled trials with statins have been inconclusive, although treatment…
read more »
Long-term evolocumab in people living with HIV
Follow-up data from the BEIJERINCK study show that treatment with evolocumab for up to 1 year was effective in HIV individuals with dyslipidaemia (1). HIV is considered a risk-enhancing factor due to the concomitant presence of underlying infection (chronic inflammation, immune dysregulation, and metabolic abnormalities…
read more »
Introducing another PCSK9 inhibitor – recaticimab
A recent report highlights therapeutic potential for recaticimab, a humanized monoclonal antibody targeting PCSK9, with LDL cholesterol reductions ranging from 50-60%, when added to statin therapy (1). Recaticimab (SHR-1209) is the latest PCSK9 monoclonal antibody which has shown efficacy in early clinical trials in healthy…
read more »
Insights from GLAGOV into residual cardiovascular risk
A new analysis from the GLAGOV (The Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound) study reaffirms the importance of multifactorial intervention to address residual cardiovascular risk among high-risk patients attaining very low levels of LDL cholesterol (1). GLAGOV…
read more »
Inclisiran available in the USA from early January 2022
Hot off the Press: Inclisiran available in the USA from early January 2022 In an ad hoc announcement (pursuant to Art. 53 LR), the US Food and Drugs Administration approved the use of inclisiran, the siRNA therapy for hypercholesterolaemia. Inclisiran is the first and only…
read more »
News from FOURIER: Benefit with evolocumab across all vascular territories
In this latest analysis from the FOURIER trial, treatment with evolocumab reduced acute arterial events in coronary, cerebro- and peripheral vascular territories with a robust effect over time. FOURIER (Further Cardiovascular OUtcomes Research With PCSK9 Inhibition in Subjects with Elevated Risk) was a landmark trial…
read more »
More insights from ORION
News from AHA Scientific Sessions 2021 Baseline glycaemic status or body mass index (BMI) did not impact the efficacy of inclisiran, according to two post hoc analyses of the ORION trials. The first poster presentation reported findings from a post hoc analysis of the ORION-10…
read more »
Long-term evinacumab in homozygous FH
News from AHA Scientific Sessions 2021 Evinacumab was the focus of two presentations in patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol). Homozygous FH is a rare genetic lipid disorder, which is characterized by markedly elevated low-density lipoprotein (LDL) cholesterol levels from birth and…
read more »
Combination alirocumab-evinacumab in homozygous FH
News from AHA Scientific Sessions 2021 Combination treatment with alirocumab plus the angiopoietin-like 3 (ANGPTL3) inhibitor evinacumab, on top of lipid lowering therapy, reduced LDL cholesterol levels by more than 60%, according to a post hoc analysis presented at AHA Scientific Sessions. This report analysed…
read more »
